

Issue **03** 2023



MicroPort Neurotech™ Receives MDSAP Certificate

MicroPort NeuroTech Limited (MicroPort NeuroTech™) recently announced that it has received a Medical Device Single Audit Program (MDSAP) certificate from the Technischer Überwachungs-Verein (TÜV SÜD), an international notified body, certifying MicroPort NeuroTech™'s compliance with both ISO13485:2016 standards and the regulatory requirements in the United States, Australia, Brazil, Canada and Japan, which lays the groundwork and provides the momentum for the company's global development by effectively reducing the audit cost of products to enter global markets.

MicroPort NeuroTech™ always adheres to the quality policy of "striving for innovation, focusing on providing safe and reliable products for patients, helping them improve the quality of life" and strictly controls product quality management. The Company's quality management system is developed on the ISO 13485:2016 standard as the fundamental framework and incorporates national or regional regulatory requirements of target markets. To date, the system is compliant with relevant regulations and standard requirements of regions including China, the European Union, the United States, Brazil, Japan, South Korea and Canada.

Obtaining the MDSAP quality system certificate will make MicroPort NeuroTech™ products more advantageous and accessible in international markets, helping the company accelerate its worldwide expansion strategy. In the future, MicroPort NeuroTech™ will continue its commitment to providing high-quality and innovative products to more countries and regions around the world to benefit more patients with cerebrovascular disease.







Investor Newsletter



For more information, please contact:

Martin Sun

Chief Financial Officer MicroPort Scientific Corporation

Tel: (86)(21) 38954600

Email: ir@microport.com

Leanne Li

Board Secretary & VP of Securities Affairs MicroPort Scientific Corporation

Tel: (86)(21) 38954600

Email: ir@microport.com